Patient status at 6-year data cutoff
| . | No. (%) . |
|---|---|
| Still on imatinib study therapy | 199 (44) |
| Discontinued imatinib study therapy | 255 (56) |
| Unsatisfactory therapeutic effect* | 132 (29) |
| Withdrew consent/lost to follow-up/protocol violation/administrative problems | 63 (14) |
| Adverse event/abnormal laboratory value | 35 (8) |
| Allogeneic stem-cell transplantation | 6 (1) |
| Death | 19 (4) |
| . | No. (%) . |
|---|---|
| Still on imatinib study therapy | 199 (44) |
| Discontinued imatinib study therapy | 255 (56) |
| Unsatisfactory therapeutic effect* | 132 (29) |
| Withdrew consent/lost to follow-up/protocol violation/administrative problems | 63 (14) |
| Adverse event/abnormal laboratory value | 35 (8) |
| Allogeneic stem-cell transplantation | 6 (1) |
| Death | 19 (4) |
N = 454.
“Unsatisfactory therapeutic effect” was counted as progression. See text for details.